Yogev, O.
Almeida, G.S.
Barker, K.T.
George, S.L.
Kwok, C.
Campbell, J.
Zarowiecki, M.
Kleftogiannis, D.
Smith, L.M.
Hallsworth, A.
Berry, P.
Möcklinghoff, T.
Webber, H.T.
Danielson, L.S.
Buttery, B.
Calton, E.A.
da Costa, B.M.
Poon, E.
Jamin, Y.
Lise, S.
Veal, G.J.
Sebire, N.
Robinson, S.P.
Anderson, J.
Chesler, L.
(2019). In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. Cancer research,
Vol.79
(20),
pp. 5382-5393.
Zormpas-Petridis, K.
Failmezger, H.
Roxanis, I.
Blackledge, M.D.
Jamin, Y.
Yuan, Y.
(2018). Capturing global spatial context for accurate cell classification in skin cancer histology. Corr,
Vol.abs/1808.02355.
Tucker, E.R.
Tall, J.R.
Danielson, L.S.
Gowan, S.
Jamin, Y.
Robinson, S.P.
Banerji, U.
Chesler, L.
(2017). Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Molecular oncology,
Vol.11
(8),
pp. 996-1006.
Almeida, G.S.
Panek, R.
Hallsworth, A.
Webber, H.
Papaevangelou, E.
Boult, J.K.
Jamin, Y.
Chesler, L.
Robinson, S.P.
(2017). Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform. British journal of cancer,
Vol.117
(6),
pp. 791-800.
Guan, J.
Tucker, E.R.
Wan, H.
Chand, D.
Danielson, L.S.
Ruuth, K.
El Wakil, A.
Witek, B.
Jamin, Y.
Umapathy, G.
Robinson, S.P.
Johnson, T.W.
Smeal, T.
Martinsson, T.
Chesler, L.
Palmer, R.H.
Hallberg, B.
(2016). The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Disease models & mechanisms,
Vol.9
(9),
pp. 941-952.
Hill, D.K.
Kim, E.
Teruel, J.R.
Jamin, Y.
Widerøe, M.
Søgaard, C.D.
Størkersen, Ø.
Rodrigues, D.N.
Heindl, A.
Yuan, Y.
Bathen, T.F.
Moestue, S.A.
(2016). Diffusion-weighted MRI for early detection and characterization of prostate cancer in the transgenic adenocarcinoma of the mouse prostate model. Journal of magnetic resonance imaging,
Vol.43
(5),
pp. 1207-1217.
Vaughan, L.
Clarke, P.A.
Barker, K.
Chanthery, Y.
Gustafson, C.W.
Tucker, E.
Renshaw, J.
Raynaud, F.
Li, X.
Burke, R.
Jamin, Y.
Robinson, S.P.
Pearson, A.
Maira, M.
Weiss, W.A.
Workman, P.
Chesler, L.
(2016). Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget,
Vol.7
(36).
Osborne, J.D.
Matthews, T.P.
McHardy, T.
Proisy, N.
Cheung, K.-.
Lainchbury, M.
Brown, N.
Walton, M.I.
Eve, P.D.
Boxall, K.J.
Hayes, A.
Henley, A.T.
Valenti, M.R.
De Haven Brandon, A.K.
Box, G.
Jamin, Y.
Robinson, S.P.
Westwood, I.M.
van Montfort, R.L.
Leonard, P.M.
Lamers, M.B.
Reader, J.C.
Aherne, G.W.
Raynaud, F.I.
Eccles, S.A.
Garrett, M.D.
Collins, I.
(2016). Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). J med chem,
Vol.59
(11),
pp. 5221-5237.
show abstract
Multiparameter optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles resulted in the identification of a potent and selective oral CHK1 preclinical development candidate with in vivo efficacy as a potentiator of deoxyribonucleic acid (DNA) damaging chemotherapy and as a single agent. Cellular mechanism of action assays were used to give an integrated assessment of compound selectivity during optimization resulting in a highly CHK1 selective adenosine triphosphate (ATP) competitive inhibitor. A single substituent vector directed away from the CHK1 kinase active site was unexpectedly found to drive the selective cellular efficacy of the compounds. Both CHK1 potency and off-target human ether-a-go-go-related gene (hERG) ion channel inhibition were dependent on lipophilicity and basicity in this series. Optimization of CHK1 cellular potency and in vivo pharmacokinetic-pharmacodynamic (PK-PD) properties gave a compound with low predicted doses and exposures in humans which mitigated the residual weak in vitro hERG inhibition..
Yogev, O.
Barker, K.
Sikka, A.
Almeida, G.
Hallsworth, A.
Smith, L.
Jamin, Y.
Ruddle, R.
Koers, A.
Webber, H.
Raynaud, F.
Popov, S.
Jones, C.
Petrie, K.
Robinson, S.
Keun, H.
Chesler, L.
(2016). p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. Cancer research,
.
Jamin, Y.
Boult, J.K.
Li, J.
Popov, S.
Garteiser, P.
Ulloa, J.L.
Cummings, C.
Box, G.
Eccles, S.A.
Jones, C.
Waterton, J.C.
Bamber, J.C.
Sinkus, R.
Robinson, S.P.
(2015). Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography. Cancer res,
Vol.75
(7),
pp. 1216-1224.
show abstract
Malignant tumors are typically associated with altered rigidity relative to normal host tissue. Magnetic resonance elastography (MRE) enables the noninvasive quantitation of the mechanical properties of deep-seated tissue following application of an external vibrational mechanical stress to that tissue. In this preclinical study, we used MRE to quantify (kPa) the elasticity modulus Gd and viscosity modulus Gl of three intracranially implanted glioma and breast metastatic tumor models. In all these brain tumors, we found a notable softness characterized by lower elasticity and viscosity than normal brain parenchyma, enabling their detection on Gd and Gl parametric maps. The most circumscribed tumor (U-87 MG glioma) was the stiffest, whereas the most infiltrative tumor (MDA-MB-231 metastatic breast carcinoma) was the softest. Tumor cell density and microvessel density correlated significantly and positively with elasticity and viscosity, whereas there was no association with the extent of collagen deposition or myelin fiber entrapment. In conclusion, although malignant tumors tend to exhibit increased rigidity, intracranial tumors presented as remarkably softer than normal brain parenchyma. Our findings reinforce the case for MRE use in diagnosing and staging brain malignancies, based on the association of different tumor phenotypes with different mechanical properties..
Papaevangelou, E.
Almeida, G.S.
Jamin, Y.
Robinson, S.P.
deSouza, N.M.
(2015). Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy. British journal of cancer,
Vol.112
(9),
pp. 1471-1479.
Dolman, M.E.
Poon, E.
Ebus, M.E.
den Hartog, I.J.
van Noesel, C.J.
Jamin, Y.
Hallsworth, A.
Robinson, S.P.
Petrie, K.
Sparidans, R.W.
Kok, R.J.
Versteeg, R.
Caron, H.N.
Chesler, L.
Molenaar, J.J.
(2015). Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical cancer research,
Vol.21
(22),
pp. 5100-5109.
O’Connor, J.P.
Boult, J.K.
Jamin, Y.
Babur, M.
Finegan, K.G.
Williams, K.J.
Little, R.A.
Jackson, A.
Parker, G.J.
Reynolds, A.R.
Waterton, J.C.
Robinson, S.P.
(2015). Oxygen enhanced MRI accurately identifies, quantifies, and maps hypoxia in preclinical cancer models. Cancer research,
(in press).
O'Connor, J.P.
Boult, J.K.
Jamin, Y.
Babur, M.
Finegan, K.G.
Williams, K.J.
Reynolds, A.R.
Little, R.A.
Jackson, A.
Parker, G.J.
Waterton, J.C.
Robinson, S.P.
(2015). Oxygen-enhanced MRI can accurately identify, quantify and map tumour hypoxia in preclinical models. Cancer imaging,
Vol.15
(Suppl 1),
pp. P9-P9.
Li, J.
Jamin, Y.
Boult, J.K.
Cummings, C.
Waterton, J.C.
Ulloa, J.
Sinkus, R.
Bamber, J.C.
Robinson, S.P.
(2014). Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography. Br j cancer,
Vol.110
(7),
pp. 1727-1732.
show abstract
BACKGROUND: Magnetic resonance elastography (MRE) is an emerging imaging technique that affords non-invasive quantitative assessment and visualization of tissue mechanical properties in vivo. METHODS: In this study, MRE was used to quantify (kPa) the absolute value of the complex shear modulus |G*|, elasticity Gd and viscosity Gl of SW620 human colorectal cancer xenografts before and 24 h after treatment with either 200 mg kg(-1) of the vascular disrupting agent ZD6126 (N-acetylcolchinol-O-phosphate) or vehicle control, and the data were compared with changes in water diffusivity measured by diffusion-weighted magnetic resonance imaging. RESULTS: A heterogeneous distribution of |G*|, Gd and Gl was observed pre-treatment with an intertumoral coefficient of variation of 13% for |G*|. There were no significant changes in the vehicle-treated cohort. In contrast, ZD6126 induced a significant decrease in the tumour-averaged |G*| (P<0.01), Gd (P<0.01) and Gl (P<0.05), and this was associated with histologically confirmed central necrosis. This reduction in tumour viscoelasticity occurred at a time when no significant change in tumour apparent diffusion coefficient (ADC) was observed. CONCLUSIONS: These data demonstrate that MRE can provide early imaging biomarkers for treatment-induced tumour necrosis..
Jamin, Y.
Eykyn, T.R.
Poon, E.
Springer, C.J.
Robinson, S.P.
(2014). Detection of the prodrug-activating enzyme carboxypeptidase G2 activity with chemical exchange saturation transfer magnetic resonance. Mol imaging biol,
Vol.16
(2),
pp. 152-157.
show abstract
PURPOSE: The purpose of this study is to evaluate if the differential exchange rates with bulk water between amine and amide protons can be exploited using chemical exchange saturation transfer magnetic resonance (CEST-MR) to monitor the release of glutamate induced by carboxypeptidase G2 (CPG2), an enzyme utilized in cancer gene therapy. PROCEDURES: Z spectra of solutions of the CPG2 substrate, 3,5-difluorobenzoyl-L-glutamate (amide), and glutamate (amine) were acquired at 11.7 T, 37 °C, across different pH (5-8). The ability of CEST-MR to monitor CPG2-mediated release of glutamate was assessed in extracts of CPG2-expressing cancer cells and purified solution of CPG2. RESULTS: The addition of CPG2 to a solution containing 3,5-difluorobenzoyl-L-glutamate led to a marked and progressively increasing CEST effect (+3 ppm), concomitant with the time-dependent release of glutamate induced by CPG2. CONCLUSION: CEST-MR allows the detection of CPG2 activity in vitro and supports the translation of CEST-MRI to assess CPG2-based gene therapy in vivo..
Jamin, Y.
Glass, L.
Hallsworth, A.
George, R.
Koh, D.-.
Pearson, A.D.
Chesler, L.
Robinson, S.P.
(2014). Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. Plos one,
Vol.9
(3),
p. e92886.
show abstract
The early identification of children presenting ALK(F1174L)-mutated neuroblastoma, which are associated with resistance to the promising ALK inhibitor crizotinib and a marked poorer prognosis, has become a clinical priority. In comparing the radiology of the novel Th-ALK(F1174L)/Th-MYCN and the well-established Th-MYCN genetically-engineered murine models of neuroblastoma using MRI, we have identified a marked ALK(F1174L)-driven vascular phenotype. We demonstrate that quantitation of the transverse relaxation rate R2* (s(-1)) using intrinsic susceptibility-MRI under baseline conditions and during hyperoxia, can robustly discriminate this differential vascular phenotype, and identify MYCN-driven tumors harboring the ALK(F1174L) mutation with high specificity and selectivity. Intrinsic susceptibility-MRI could thus potentially provide a non-invasive and clinically-exploitable method to help identifying children with MYCN-driven neuroblastoma harboring the ALK(F1174L) mutation at the time of diagnosis..
Baker, L.C.
Boult, J.K.
Jamin, Y.
Gilmour, L.D.
Walker-Samuel, S.
Burrell, J.S.
Ashcroft, M.
Howe, F.A.
Griffiths, J.R.
Raleigh, J.A.
van der Kogel, A.J.
Robinson, S.P.
(2013). Evaluation and immunohistochemical qualification of carbogen-induced ΔR₂ as a noninvasive imaging biomarker of improved tumor oxygenation. Int j radiat oncol biol phys,
Vol.87
(1),
pp. 160-167.
show abstract
PURPOSE: To evaluate and histologically qualify carbogen-induced ΔR2 as a noninvasive magnetic resonance imaging biomarker of improved tumor oxygenation using a double 2-nitroimidazole hypoxia marker approach. METHODS AND MATERIALS: Multigradient echo images were acquired from mice bearing GH3 prolactinomas, preadministered with the hypoxia marker CCI-103F, to quantify tumor R2 during air breathing. With the mouse remaining positioned within the magnet bore, the gas supply was switched to carbogen (95% O2, 5% CO2), during which a second hypoxia marker, pimonidazole, was administered via an intraperitoneal line, and an additional set of identical multigradient echo images acquired to quantify any changes in tumor R2. Hypoxic fraction was quantified histologically using immunofluorescence detection of CCI-103F and pimonidazole adduct formation from the same whole tumor section. Carbogen-induced changes in tumor pO2 were further validated using the Oxylite fiberoptic probe. RESULTS: Carbogen challenge significantly reduced mean tumor R2 from 116 ± 13 s(-1) to 97 ± 9 s(-1) (P<.05). This was associated with a significantly lower pimonidazole adduct area (2.3 ± 1%), compared with CCI-103F (6.3 ± 2%) (P<.05). A significant correlation was observed between ΔR2 and Δhypoxic fraction (r=0.55, P<.01). Mean tumor pO2 during carbogen breathing significantly increased from 6.3 ± 2.2 mm Hg to 36.0 ± 7.5 mm Hg (P<.01). CONCLUSIONS: The combined use of intrinsic susceptibility magnetic resonance imaging with a double hypoxia marker approach corroborates carbogen-induced ΔR2 as a noninvasive imaging biomarker of increased tumor oxygenation..
Jamin, Y.
Tucker, E.R.
Poon, E.
Popov, S.
Vaughan, L.
Boult, J.K.
Webber, H.
Hallsworth, A.
Baker, L.C.
Jones, C.
Koh, D.-.
Pearson, A.D.
Chesler, L.
Robinson, S.P.
(2013). Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma. Radiology,
Vol.266
(1),
pp. 130-140.
show abstract
PURPOSE: To evaluate noninvasive and clinically translatable magnetic resonance (MR) imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of aggressive, MYCN-amplified neuroblastoma. MATERIALS AND METHODS: All experiments were performed in accordance with the local ethical review panel and the UK Home Office Animals Scientific Procedures Act 1986 and with the UK National Cancer Research Institute guidelines for the welfare of animals in cancer research. Multiparametric MR imaging was performed of abdominal tumors found in the TH-MYCN model. T2-weighted MR imaging, quantitation of native relaxation times T1 and T2, the relaxation rate R2*, and dynamic contrast-enhanced MR imaging were used to monitor tumor response to cyclophosphamide (25 mg/kg), the vascular disrupting agent ZD6126 (200 mg/kg), or the antiangiogenic agent cediranib (6 mg/kg, daily). Any significant changes in the measured parameters, and in the magnitude of the changes after treatment between treated and control cohorts, were identified by using Student two-tailed paired and unpaired t test, respectively, with a 5% level of significance. RESULTS: Treatment with cyclophosphamide or cediranib induced a 54% or 20% reduction in tumor volume at 48 hours, respectively (P < .005 and P < .005, respectively; P < .005 and P < .005 versus control, respectively). Treatment with ZD6126 induced a 45% reduction in mean tumor volume 24 hours after treatment (P < .005; P < .005 versus control). The antitumor activity of cyclophosphamide, cediranib, and ZD6126 was consistently associated with a decrease in tumor T1 (P < .005, P < .005, and P < .005, respectively; P < .005, P < .005, and P < .005 versus control, respectively) and with a correlation between therapy-induced changes in native T1 and changes in tumor volume (r = 0.56; P < .005). Tumor response to cediranib was also associated with a decrease in the dynamic contrast-enhanced MR imaging-derived volume transfer constant (P = .07; P < .05 versus control) and enhancing fraction (P < .05; P < .01 versus control), and an increase in R2* (P < .005; P < .05 versus control). CONCLUSION: The T1 relaxation time is a robust noninvasive imaging biomarker of response to therapy in tumors in TH-MYCN mice, which emulate high-risk neuroblastoma in children. T1 measurements can be readily implemented on clinical MR systems and should be investigated in translational clinical trials of new targeted therapies for pediatric neuroblastoma. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.12120128/-/DC1..
Hill, D.K.
Orton, M.R.
Mariotti, E.
Boult, J.K.
Panek, R.
Jafar, M.
Parkes, H.G.
Jamin, Y.
Miniotis, M.F.
Al-Saffar, N.M.
Beloueche-Babari, M.
Robinson, S.P.
Leach, M.O.
Chung, Y.-.
Eykyn, T.R.
(2013). Model Free Approach to Kinetic Analysis of Real-Time Hyperpolarized C-13 Magnetic Resonance Spectroscopy Data. Plos one,
Vol.8
(9).
Burrell, J.S.
Walker-Samuel, S.
Baker, L.C.
Boult, J.K.
Jamin, Y.
Halliday, J.
Waterton, J.C.
Robinson, S.P.
(2013). Exploring ΔR(2) * and ΔR(1) as imaging biomarkers of tumor oxygenation. J magn reson imaging,
Vol.38
(2),
pp. 429-434.
show abstract
PURPOSE: To investigate the combined use of hyperoxia-inducedΔR(2) * and ΔR(1) as a noninvasive imaging biomarker of tumor hypoxia. MATERIALS AND METHODS: MRI was performed on rat GH3 prolactinomas (n = 6) and human PC3 prostate xenografts (n = 6) propagated in nude mice. multiple gradient echo and inversion recovery truefisp images were acquired from identical transverse slices to quantify tumor R(2) * and R(1)before and during carbogen (95% O2 /5% CO2 ) challenge, and correlates of ΔR(2) * and ΔR(1) assessed. RESULTS: Mean baseline R(2) * and R(1) were 119 ± 7 s(-1) and 0.6 ± 0.03 s(-1) for GH3 prolactinomas and 77 ± 12 s(-1) and 0.7 ± 0.02 s(-1) for PC3 xenografts, respectively. During carbogen breathing, mean ΔR(2) * and ΔR(1) were -20 ± 8 s(-1) and 0.08 ± 0.03 s(-1) for GH3 and -0.5 ± 1 s(-1) and 0.2 ± 0.08 s(-1) for the PC3 tumors, respectively. A pronounced relationship betweenΔR(2) * and ΔR(1) was revealed. CONCLUSION: Considering the blood oxygen-hemoglobin dissociation curve, fast R2 * suggested that GH3 prolactinomas were more hypoxic at baseline, and their carbogen response dominated by increased hemoglobin oxygenation, evidenced by highly negative ΔR(2) *. PC3 tumors were less hypoxic at baseline, and their response to carbogen dominated by increased dissolved oxygen, evidenced by highly positive ΔR(1) . Because the two biomarkers are sensitive to different oxygenation ranges, the combination of ΔR(2) * and ΔR(1) may better characterize tumor hypoxia than each alone..
Brockmann, M.
Poon, E.
Berry, T.
Carstensen, A.
Deubzer, H.E.
Rycak, L.
Jamin, Y.
Thway, K.
Robinson, S.P.
Roels, F.
Witt, O.
Fischer, M.
Chesler, L.
Eilers, M.
(2013). Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer cell,
Vol.24
(1),
pp. 75-89.
show abstract
Amplification of MYCN is a driver mutation in a subset of human neuroendocrine tumors, including neuroblastoma. No small molecules that target N-Myc, the protein encoded by MYCN, are clinically available. N-Myc forms a complex with the Aurora-A kinase, which protects N-Myc from proteasomal degradation. Although stabilization of N-Myc does not require the catalytic activity of Aurora-A, we show here that two Aurora-A inhibitors, MLN8054 and MLN8237, disrupt the Aurora-A/N-Myc complex and promote degradation of N-Myc mediated by the Fbxw7 ubiquitin ligase. Disruption of the Aurora-A/N-Myc complex inhibits N-Myc-dependent transcription, correlating with tumor regression and prolonged survival in a mouse model of MYCN-driven neuroblastoma. We conclude that Aurora-A is an accessible target that makes destabilization of N-Myc a viable therapeutic strategy. .
Hill, D.K.
Jamin, Y.
Orton, M.R.
Tardif, N.
Parkes, H.G.
Robinson, S.P.
Leach, M.O.
Chung, Y.-.
Eykyn, T.R.
(2013). ¹H NMR and hyperpolarized ¹³C NMR assays of pyruvate-lactate: a comparative study. Nmr biomed,
Vol.26
(10),
pp. 1321-1325.
show abstract
Pyruvate-lactate exchange is mediated by the enzyme lactate dehydrogenase (LDH) and is central to the altered energy metabolism in cancer cells. The measurement of exchange kinetics using hyperpolarized (13) C NMR has provided a biomarker of response to novel therapeutics. However, the observable signal is restricted to the exchanging hyperpolarized (13) C pools and the endogenous pools of (12) C-labelled metabolites are invisible in these measurements. In this study, we investigated an alternative in vitro (1) H NMR assay, using [3-(13) C]pyruvate, and compared the measured kinetics with a hyperpolarized (13) C NMR assay, using [1-(13) C]pyruvate, under the same conditions in human colorectal carcinoma SW1222 cells. The apparent forward reaction rate constants (kPL ) derived from the two assays showed no significant difference, and both assays had similar reproducibility (kPL = 0.506 ± 0.054 and kPL = 0.441 ± 0.090 nmol/s/10(6) cells; mean ± standard deviation; n = 3); (1) H, (13) C assays, respectively). The apparent backward reaction rate constant (kLP ) could only be measured with good reproducibility using the (1) H NMR assay (kLP = 0.376 ± 0.091 nmol/s/10(6) cells; mean ± standard deviation; n = 3). The (1) H NMR assay has adequate sensitivity to measure real-time pyruvate-lactate exchange kinetics in vitro, offering a complementary and accessible assay of apparent LDH activity..
Beloueche-Babari, M.
Jamin, Y.
Arunan, V.
Walker-Samuel, S.
Revill, M.
Smith, P.D.
Halliday, J.
Waterton, J.C.
Barjat, H.
Workman, P.
Leach, M.O.
Robinson, S.P.
(2013). Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. Br j cancer,
Vol.109
(6),
pp. 1562-1569.
show abstract
BACKGROUND: Non-invasive imaging biomarkers underpin the development of molecularly targeted anti-cancer drugs. This study evaluates tumour apparent diffusion coefficient (ADC), measured by diffusion-weighted magnetic resonance imaging (DW-MRI), as a biomarker of response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in human tumour xenografts. METHODS: Nude mice bearing human BRAF(V600D) WM266.4 melanoma or BRAF(V600E) Colo205 colon carcinoma xenografts were treated for 4 days with vehicle or selumetinib. DW-MRI was performed before and 2 h after the last dose and excised tumours analysed for levels of phospho-ERK1/2, cleaved caspase 3 (CC3) and necrosis. RESULTS: Selumetinib treatment induced tumour stasis and reduced ERK1/2 phosphorylation in both WM266.4 and Colo205 tumour xenografts. Relative to day 0, mean tumour ADC was unchanged in the control groups but was significantly increased by up to 1.6-fold in selumetinib-treated WM266.4 and Colo205 tumours. Histological analysis revealed a significant increase in necrosis in selumetinib-treated WM266.4 and Colo205 xenografts and CC3 staining in selumetinib-treated Colo205 tumours relative to controls. CONCLUSION: Changes in ADC following treatment with the MEK1/2 inhibitor selumetinib in responsive human tumour xenografts were concomitant with induction of tumour cell death. ADC may provide a useful non-invasive pharmacodynamic biomarker for early clinical assessment of response to selumetinib and other MEK-ERK1/2 signalling-targeted therapies..
Hill, D.K.
Orton, M.R.
Mariotti, E.
Boult, J.K.
Panek, R.
Jafar, M.
Parkes, H.G.
Jamin, Y.
Miniotis, M.F.
Al-Saffar, N.M.
Beloueche-Babari, M.
Robinson, S.P.
Leach, M.O.
Chung, Y.-.
Eykyn, T.R.
(2013). Model free approach to kinetic analysis of real-time hyperpolarized 13C magnetic resonance spectroscopy data. Plos one,
Vol.8
(9),
p. e71996.
show abstract
Real-time detection of the rates of metabolic flux, or exchange rates of endogenous enzymatic reactions, is now feasible in biological systems using Dynamic Nuclear Polarization Magnetic Resonance. Derivation of reaction rate kinetics from this technique typically requires multi-compartmental modeling of dynamic data, and results are therefore model-dependent and prone to misinterpretation. We present a model-free formulism based on the ratio of total areas under the curve (AUC) of the injected and product metabolite, for example pyruvate and lactate. A theoretical framework to support this novel analysis approach is described, and demonstrates that the AUC ratio is proportional to the forward rate constant k. We show that the model-free approach strongly correlates with k for whole cell in vitro experiments across a range of cancer cell lines, and detects response in cells treated with the pan-class I PI3K inhibitor GDC-0941 with comparable or greater sensitivity. The same result is seen in vivo with tumor xenograft-bearing mice, in control tumors and following drug treatment with dichloroacetate. An important finding is that the area under the curve is independent of both the input function and of any other metabolic pathways arising from the injected metabolite. This model-free approach provides a robust and clinically relevant alternative to kinetic model-based rate measurements in the clinical translation of hyperpolarized (13)C metabolic imaging in humans, where measurement of the input function can be problematic. .
Boult, J.K.
Jamin, Y.
Jacobs, V.
Gilmour, L.D.
Walker-Samuel, S.
Halliday, J.
Elvin, P.
Ryan, A.J.
Waterton, J.C.
Robinson, S.P.
(2012). False-negative MRI biomarkers of tumour response to targeted cancer therapeutics. Br j cancer,
Vol.106
(12),
pp. 1960-1966.
show abstract
BACKGROUND: Non-invasive quantitative imaging biomarkers are essential for the evaluation of novel targeted therapeutics. Before deployment in clinical trials, such imaging biomarkers require qualification, typically through pre-clinical identification of imaging-pathology correlates. METHODS: First, in investigating imaging biomarkers of invasion, the response of orthotopic murine PC3 prostate xenografts to the Src inhibitor saracatinib was assessed using susceptibility contrast MRI. Second, the longitudinal response of chemically induced rat mammary adenocarcinomas to the VEGFR2 inhibitor vandetanib was monitored by intrinsic susceptibility MRI, to identify the time window of transient vascular normalisation. RESULTS: No significant differences in fractional blood volume (%), vessel calibre (μm), native T(1) (ms) or apparent water diffusion coefficient were determined, despite reduced expression of activated Fak and paxillin in the saracatinib cohort. Treatment with vandetanib elicited a 60% antitumour response (P<0.01), 80% inhibition in vessel density (P<0.05) and reduction in hypoxia (P<0.05). There was, however, no significant change in tumour baseline R(2)* (s(-1)) or carbogen-induced ΔR(2)* with treatment. CONCLUSION: Reporting negative imaging biomarker responses is important, to avoid the risk of clinical trials using the same biomarkers being undertaken with a false expectation of success, and the abandonment of promising new therapeutics based on a false-negative imaging biomarker response being mistaken for a true-negative..
Baker, L.C.
Boult, J.K.
Walker-Samuel, S.
Chung, Y.-.
Jamin, Y.
Ashcroft, M.
Robinson, S.P.
(2012). The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function. Br j cancer,
Vol.106
(10),
pp. 1638-1647.
show abstract
BACKGROUND: Hypoxia-inducible factor-1 (HIF-1) mediates the transcriptional response to hypoxic stress, promoting tumour progression and survival. This study investigated the acute effects of the small-molecule HIF-pathway inhibitor NSC-134754. METHODS: Human PC-3LN5 prostate cancer cells were treated with NSC-134754 for 24 h in hypoxia. Orthotopic prostate tumour-bearing mice were treated with a single dose of NSC-134754 for 6, 24 or 48 h. Treatment response was measured using magnetic resonance spectroscopy and imaging. Ex-vivo histological validation of imaging findings was also sought. RESULTS: In vitro, NSC-134754 significantly reduced lactate production and glucose uptake (P<0.05), while significantly increasing intracellular glucose (P<0.01) and glutamine uptake/metabolism (P<0.05). Increased glutamine metabolism was independent of c-Myc, a factor also downregulated by NSC-134754. In vivo, a significantly higher tumour apparent diffusion coefficient was determined 24 h post-treatment (P<0.05), with significantly higher tumour necrosis after 48 h (P<0.05). NSC-134754-treated tumours revealed lower expression of HIF-1α and glucose transporter-1, at 6 and 24 h respectively, while a transient increase in tumour hypoxia was observed after 24 h. Vessel perfusion/flow and vascular endothelial growth factor levels were unchanged with treatment. CONCLUSION: NSC-134754 induces metabolic alterations in vitro and early anti-tumour activity in vivo, independent of changes in vascular function. Our data support the further evaluation of NSC-134754 as an anti-cancer agent..
Berry, T.
Luther, W.
Bhatnagar, N.
Jamin, Y.
Poon, E.
Sanda, T.
Pei, D.
Sharma, B.
Vetharoy, W.R.
Hallsworth, A.
Ahmad, Z.
Barker, K.
Moreau, L.
Webber, H.
Wang, W.
Liu, Q.
Perez-Atayde, A.
Rodig, S.
Cheung, N.-.
Raynaud, F.
Hallberg, B.
Robinson, S.P.
Gray, N.S.
Pearson, A.D.
Eccles, S.A.
Chesler, L.
George, R.E.
(2012). The ALK(F1174L) Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. Cancer cell,
Vol.22
(1),
pp. 117-130.
Burrell, J.S.
Bradley, R.S.
Walker-Samuel, S.
Jamin, Y.
Baker, L.C.
Boult, J.K.
Withers, P.J.
Halliday, J.
Waterton, J.C.
Robinson, S.P.
(2012). MRI measurements of vessel calibre in tumour xenografts: comparison with vascular corrosion casting. Microvasc res,
Vol.84
(3),
pp. 323-329.
show abstract
Vessel size index (R(v), μm) has been proposed as a quantitative magnetic resonance imaging (MRI) derived imaging biomarker in oncology, for the non-invasive assessment of tumour blood vessel architecture and vascular targeted therapies. Appropriate pre-clinical evaluation of R(v) in animal tumour models will improve the interpretation and guide the introduction of the biomarker into clinical studies. The objective of this study was to compare R(v) measured in vivo with vessel size measurements from high-resolution X-ray computed tomography (μCT) of vascular corrosion casts measured post mortem from the same tumours, with and without vascular targeted therapy. MRI measurements were first acquired from subcutaneous SW1222 colorectal xenografts in mice following treatment with 0 (n=6), 30 (n=6) or 200 mg/kg (n=3) of the vascular disrupting agent ZD6126. The mice were then immediately infused with a low viscosity resin and, following polymerisation and maceration of surrounding tissues, the resulting tumour vascular casts were dissected and subsequently imaged using an optimised μCT imaging approach. Vessel diameters were not measurable by μCT in the 200 mg/kg group as the high dose of ZD6126 precluded delivery of the resin to the tumour vascular bed. The mean R(v) for the three treatment groups was 24, 23 and 23.5 μm respectively; the corresponding μCT measurements from corrosion casts from the 0 and 30 mg/kg cohorts were 25 and 28 μm. The strong association between the in vivo MRI and post mortem μCT values supports the use of R(v) as an imaging biomarker in clinical trials of investigational vascular targeted therapies..
Bielen, A.
Box, G.
Perryman, L.
Bjerke, L.
Popov, S.
Jamin, Y.
Jury, A.
Valenti, M.
Brandon, A.D.
Martins, V.
Romanet, V.
Jeay, S.
Raynaud, F.I.
Hofmann, F.
Robinson, S.P.
Eccles, S.A.
Jones, C.
(2012). Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. Proc natl acad sci u s a,
Vol.109
(20),
pp. E1267-E1276.
show abstract
We have previously demonstrated an increased DNA copy number and expression of IGF1R to be associated with poor outcome in Wilms tumors. We have now tested whether inhibiting this receptor may be a useful therapeutic strategy by using a panel of Wilms tumor cell lines. Both genetic and pharmacological targeting resulted in inhibition of downstream signaling through PI3 and MAP kinases, G(1) cell cycle arrest, and cell death, with drug efficacy dependent on the levels of phosphorylated IGF1R. These effects were further associated with specific gene expression signatures reflecting pathway inhibition, and conferred synergistic chemosensitisation to doxorubicin and topotecan. In the in vivo setting, s.c. xenografts of WiT49 cells resembled malignant rhabdoid tumors rather than Wilms tumors. Treatment with an IGF1R inhibitor (NVP-AEW541) showed no discernable antitumor activity and no downstream pathway inactivation. By contrast, Wilms tumor cells established orthotopically within the kidney were histologically accurate and exhibited significantly elevated insulin-like growth factor-mediated signaling, and growth was significantly reduced on treatment with NVP-AEW541 in parallel with signaling pathway ablation. As a result of the paracrine effects of enhanced IGF2 expression in Wilms tumor, this disease may be acutely dependent on signaling through the IGF1 receptor, and thus treatment strategies aimed at its inhibition may be useful in the clinic. Such efficacy may be missed if only standard ectopic models are considered as a result of an imperfect recapitulation of the specific tumor microenvironment..
Walton, M.I.
Eve, P.D.
Hayes, A.
Valenti, M.R.
De Haven Brandon, A.K.
Box, G.
Hallsworth, A.
Smith, E.L.
Boxall, K.J.
Lainchbury, M.
Matthews, T.P.
Jamin, Y.
Robinson, S.P.
Aherne, G.W.
Reader, J.C.
Chesler, L.
Raynaud, F.I.
Eccles, S.A.
Collins, I.
Garrett, M.D.
(2012). CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin cancer res,
Vol.18
(20),
pp. 5650-5661.
show abstract
PURPOSE: Many tumors exhibit defective cell-cycle checkpoint control and increased replicative stress. CHK1 is critically involved in the DNA damage response and maintenance of replication fork stability. We have therefore discovered a novel potent, highly selective, orally active ATP-competitive CHK1 inhibitor, CCT244747, and present its preclinical pharmacology and therapeutic activity. EXPERIMENTAL DESIGN: Cellular CHK1 activity was assessed using an ELISA assay, and cytotoxicity a SRB assay. Biomarker modulation was measured using immunoblotting, and cell-cycle effects by flow cytometry analysis. Single-agent oral CCT244747 antitumor activity was evaluated in a MYCN-driven transgenic mouse model of neuroblastoma by MRI and in genotoxic combinations in human tumor xenografts by growth delay. RESULTS: CCT244747 inhibited cellular CHK1 activity (IC(50) 29-170 nmol/L), significantly enhanced the cytotoxicity of several anticancer drugs, and abrogated drug-induced S and G(2) arrest in multiple tumor cell lines. Biomarkers of CHK1 (pS296 CHK1) activity and cell-cycle inactivity (pY15 CDK1) were induced by genotoxics and inhibited by CCT244747 both in vitro and in vivo, producing enhanced DNA damage and apoptosis. Active tumor concentrations of CCT244747 were obtained following oral administration. The antitumor activity of both gemcitabine and irinotecan were significantly enhanced by CCT244747 in several human tumor xenografts, giving concomitant biomarker modulation indicative of CHK1 inhibition. CCT244747 also showed marked antitumor activity as a single agent in a MYCN-driven neuroblastoma. CONCLUSION: CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies..
Burrell, J.S.
Walker-Samuel, S.
Baker, L.C.
Boult, J.K.
Jamin, Y.
Ryan, A.J.
Waterton, J.C.
Halliday, J.
Robinson, S.P.
(2012). Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. Int j cancer,
Vol.131
(8),
pp. 1854-1862.
show abstract
The recently described combined carbogen USPIO (CUSPIO) magnetic resonance imaging (MRI) method uses spatial correlations in independent imaging biomarkers to assess specific components of tumor vascular structure and function. Our study aimed to evaluate CUSPIO biomarkers for the assessment of tumor response to antiangiogenic therapy. CUSPIO imaging was performed in subcutaneous rat C6 gliomas before and 2 days after treatment with the potent VEGF-signaling inhibitor cediranib (n = 12), or vehicle (n = 12). Histological validation of Hoechst 33342 uptake (perfusion), smooth muscle actin staining (maturation), pimonidazole adduct formation (hypoxia) and necrosis were sought. Following treatment, there was a significant decrease in fractional blood volume (-43%, p < 0.01) and a significant increase in hemodynamic vascular functionality (treatment altered ΔR(2) *(carbogen) from 1.2 to -0.2 s(-1) , p < 0.05). CUSPIO imaging revealed an overall significant decrease in plasma perfusion (-27%, p < 0.05) following cediranib treatment, that was associated with selective effects on immature blood vessels. The CUSPIO responses were associated with a significant 15% reduction in Hoechst 33342 uptake (p < 0.05), but no significant difference in vascular maturation or necrosis. Additionally, treatment with cediranib resulted in a significant 40% increase in tumor hypoxia (p < 0.05). The CUSPIO imaging method provides novel and more specific biomarkers of tumor vessel maturity and vascular hemodynamics, and their response to VEGF-signaling inhibition, compared to current MR imaging biomarkers utilized in the clinic. Such biomarkers may prove effective in longitudinally monitoring tumor vascular remodeling and/or evasive resistance in response to antiangiogenic therapy..
Jamin, Y.
Smyth, L.
Robinson, S.P.
Poon, E.S.
Eykyn, T.R.
Springer, C.J.
Leach, M.O.
Payne, G.S.
(2011). Noninvasive detection of carboxypeptidase G2 activity in vivo. Nmr biomed,
Vol.24
(4),
pp. 343-350.
show abstract
The pseudomonad protein, carboxypeptidase G2 (CPG2), is a prodrug-activating enzyme utilized in the targeted chemotherapy strategies of antibody- and gene-directed enzyme prodrug therapy (ADEPT and GDEPT). We have developed a noninvasive imaging approach to monitor CPG2 activity in vivo that will facilitate the preclinical and clinical development of CPG2-based ADEPT and GDEPT strategies. Cleavage of the novel reporter probe, 3,5-difluorobenzoyl-L-glutamic acid (3,5-DFBGlu), by CPG2, in human colon adenocarcinoma WiDr xenografts engineered to stably express CPG2, was monitored using (19)F MRSI. The high signal-to-noise ratio afforded by the two MR-equivalent (19)F nuclei of 3,5-DFBGlu, and the 1.4 ppm (19)F chemical shift difference on CPG2-mediated cleavage, enabled the dynamics and quantification of the apparent pharmacokinetics of 3,5-DFBGlu and its CPG2-mediated cleavage in the tumor to be evaluated. In addition, the apparent rate of increase of 3,5-difluorobenzoic acid concentration could also provide a biomarker of CPG2 activity levels in tumors of patients undergoing CPG2-based therapies, as well as a biomarker of treatment response. The addition of in vivo reporter probes, such as 3,5-DFBGlu, to the armamentarium of prodrugs cleaved by CPG2 affords new applications for CPG2 as a gene reporter of transgene expression..
Faisal, A.
Vaughan, L.
Bavetsias, V.
Sun, C.
Atrash, B.
Avery, S.
Jamin, Y.
Robinson, S.P.
Workman, P.
Blagg, J.
Raynaud, F.I.
Eccles, S.A.
Chesler, L.
Linardopoulos, S.
(2011). The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol cancer ther,
Vol.10
(11),
pp. 2115-2123.
show abstract
Aurora kinases regulate key stages of mitosis including centrosome maturation, spindle assembly, chromosome segregation, and cytokinesis. Aurora A and B kinase overexpression has also been associated with various human cancers, and as such, they have been extensively studied as novel antimitotic drug targets. Here, we characterize the Aurora kinase inhibitor CCT137690, a highly selective, orally bioavailable imidazo[4,5-b]pyridine derivative that inhibits Aurora A and B kinases with low nanomolar IC(50) values in both biochemical and cellular assays and exhibits antiproliferative activity against a wide range of human solid tumor cell lines. CCT137690 efficiently inhibits histone H3 and transforming acidic coiled-coil 3 phosphorylation (Aurora B and Aurora A substrates, respectively) in HCT116 and HeLa cells. Continuous exposure of tumor cells to the inhibitor causes multipolar spindle formation, chromosome misalignment, polyploidy, and apoptosis. This is accompanied by p53/p21/BAX induction, thymidine kinase 1 downregulation, and PARP cleavage. Furthermore, CCT137690 treatment of MYCN-amplified neuroblastoma cell lines inhibits cell proliferation and decreases MYCN protein expression. Importantly, in a transgenic mouse model of neuroblastoma that overexpresses MYCN protein and is predisposed to spontaneous neuroblastoma formation, this compound significantly inhibits tumor growth. The potent preclinical activity of CCT137690 suggests that this inhibitor may benefit patients with MYCN-amplified neuroblastoma..
Boult, J.K.
Walker-Samuel, S.
Jamin, Y.
Leiper, J.M.
Whitley, G.S.
Robinson, S.P.
(2011). Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. J pathol,
Vol.225
(3),
pp. 344-352.
show abstract
Dimethylarginine dimethylaminohydrolase (DDAH) metabolizes the endogenous inhibitor of nitric oxide synthesis, asymmetric dimethylarginine (ADMA). Constitutive over-expression of DDAH1, the isoform primarily associated with neuronal nitric oxide synthase (nNOS) results in increased tumour growth and vascularization, and elevated VEGF secretion. To address whether DDAH1-mediated tumour growth is reliant upon the enzymatic activity of DDAH1, cell lines expressing an active site mutant of DDAH1 incapable of metabolizing ADMA were created. Xenografts derived from these cell lines grew significantly faster than those derived from control cells, yet not as fast as those over-expressing wild-type DDAH1. VEGF expression in DDAH1 mutant-expressing tumours did not differ from control tumours but was significantly lower than that of wild-type DDAH1-over-expressing tumours. Fluorescence microscopy for CD31 and pimonidazole adduct formation demonstrated that DDAH1 mutant-expressing tumours had a lower endothelial content and demonstrated less hypoxia, respectively, than wild-type DDAH1-expressing tumours. However, there was no difference in uptake of the perfusion marker Hoechst 33342. Non-invasive multiparametric quantitative MRI, including the measurement of native T(1) and T(2) relaxation times and apparent water diffusion coefficient, was indicative of higher cellularity in DDAH1-expressing xenografts, which was confirmed by histological quantification of necrosis. C6 xenografts expressing active site mutant DDAH1 displayed an intermediate phenotype between tumours over-expressing wild-type DDAH1 and control tumours. These data suggest that enhanced VEGF expression downstream of DDAH1 was dependent upon ADMA metabolism, but that the DDAH1-mediated increase in tumour growth was only partially dependent upon its enzymatic activity, and therefore must involve an as-yet unidentified mechanism. DDAH1 is an important mediator of tumour progression, but appears to have addition roles independent of its metabolism of ADMA, which need to be considered in therapeutic strategies targeted against the NO/DDAH pathway in cancer..
Vaughan, L.S.
Barker, K.
Webber, H.
Jamin, Y.
Robinson, S.
Guichard, S.
Chesler, L.
(2011). AZD8055, a combined TORC1/TORC2 inhibitor regulates Mycn protein expression and prevents neuroblastoma growth in vitro and in vivo. Cancer research,
Vol.71.
Vaughan, L.S.
Barker, K.
Webber, H.
Jamin, Y.
Robinson, S.
Guichard, S.
Chesler, L.
(2011). Abstract 4345: AZD8055, a combined TORC1/TORC2 inhibitor regulates Mycn protein expression and prevents neuroblastoma growth in vitro and in vivo. Tumor biology,
.
Jamin, Y.
Cullis, E.R.
Vaughan, L.
Koh, D.-.
Chesler, L.
Robinson, S.P.
(2010). Abstract 4189: Characterization of tumor progression and chemoresponse in a novel transgenic mouse model of neuroblastoma (TH-MYCN) using magnetic resonance imaging. Tumor biology,
.
Gabellieri, C.
Beloueche-Babari, M.
Jamin, Y.
Payne, G.S.
Leach, M.O.
Eykyn, T.R.
(2009). Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR. Nmr biomed,
Vol.22
(4),
pp. 456-461.
show abstract
Choline metabolites are widely studied in cancer research as biomarkers of malignancy and as indicators of therapeutic response. However, endogenous phosphocholine levels are determined by a number of processes that confound the interpretation of these measurements, including membrane transport rates and a series of enzyme catalysed reactions in the Kennedy pathway. Employing a dynamic (31)P NMR assay that is specific to choline kinase (ChoK) we have measured the rates of this enzyme reaction in cell lysates of MDA-MB-231 breast, PC-3 prostate and HeLa cervical cancer cells and in solutions of purified human ChoK. The rates are sensitive to inhibition by hemicholinium-3 (HC-3), a competitive ChoK inhibitor, and to N-[2-bromocinnamyl(amino)ethyl]-5-isoquinolinesulphonamide (H-89), an agent commercialized as a specific cyclic-AMP-dependent protein kinase A (PKA) inhibitor..
Jamin, Y.
Gabellieri, C.
Smyth, L.
Reynolds, S.
Robinson, S.P.
Springer, C.J.
Leach, M.O.
Payne, G.S.
Eykyn, T.R.
(2009). Hyperpolarized (13)C magnetic resonance detection of carboxypeptidase G2 activity. Magn reson med,
Vol.62
(5),
pp. 1300-1304.
show abstract
Carboxypeptidase G2 (CPG2) is a bacterial enzyme that is currently employed in a range of targeted cancer chemotherapy strategies such as gene-directed enzyme prodrug therapy (GDEPT). Employing dynamic nuclear polarization (DNP) and natural abundance (13)C magnetic resonance spectroscopy (MRS), we observed the CPG2-mediated conversion of a novel hyperpolarized reporter probe 3,5-difluorobenzoyl-L-glutamic acid (3,5-DFBGlu) to 3,5-difluorobenzoic acid (3,5-DFBA) and L-glutamic acid (L-Glu) in vitro. Isotopic labeling of the relevant nuclei with (13)C in 3,5-DFBGlu or related substrates will yield a further factor of 100 increase in the signal-to-noise. We discuss the feasibility of translating these experiments to generate metabolic images of CPG2 activity in vivo..
Robinson, S.
Boult, J.
Baker, L.
Jamin, Y.
Investigating the Vascular Phenotype of Subcutaneously and Orthotopically Propagated PC3 Prostate Cancer Xenografts Using Combined Carbogen USPIO (CUSPIO) MRI. Topics in magnetic resonance imaging,
.
Poon, E.
Jamin, Y.
Liang, T.
Waltz, S.
Kwok, C.
Hakkert, A.
Richards, M.
Urban, Z.
Thway, K.
Zied, R.
Box, G.
Ebus, M.
Barker, K.
Licciardello, M.
Sbirkov, Y.
Lazaro, G.
Danielson, L.
Tardif, N.
Almeida, G.
Christova, R.
Boysen, G.
Ford, A.
Clarke, P.
De Bono, J.
Robinson, S.
Eccles, S.
Zheleva, D.
Workman, P.
Bradner, J.
Molenaar, J.
Vivanco, I.
Bayliss, R.
Eilers, M.
Lin, C.
Chesler, L.
Pharmacological blockade of MYCN in neuroblastoma using orally-bioavailable CDK inhibitors reveals an approach widely applicable to Myc-dependent cancers. Nature medicine,
.
show abstract
Paper in submission NOT accepted.
Hill, D.K.
Heindl, A.
Zormpas-Petridis, K.
Collins, D.J.
Euceda, L.R.
Rodrigues, D.N.
Moestue, S.A.
Jamin, Y.
Koh, D.-.
Yuan, Y.
Bathen, T.F.
Leach, M.O.
Blackledge, M.D.
Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model. Frontiers in oncology,
Vol.7.
Vlachogiannis, G.
Hedayat, S.
Vatsiou, A.
Jamin, Y.
Fernandez Mateos, J.
Khan, K.
Lampis, A.
Eason, K.
Burke, R.
Rata, M.
Koh, D.-.
Tunariu, N.
Collins, D.
Hulkki, S.
Ragulan, C.
Spiteri Sagastume, I.
Moorcraft, S.Y.
Chau, I.
Rao, S.
Watkins, D.
Fotiadis, N.
Bali, M.
Darvish Damavandi, M.
Lote, H.
Eltahir, Z.
Smyth, L.
Begum, R.
Clarke, P.
Hahne, J.
Dowsett, M.
De Bono, J.
Workman, P.
Sadanandam, A.
Eccles, S.
Starling, N.
Braconi, C.
Sottoriva, A.
Robinson, S.
Cunningham, D.
Valeri, N.
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science,
.
Little, R.A.
Jamin, Y.
Boult, J.K.
Naish, J.H.
Watson, Y.
Cheung, S.
Holliday, K.F.
Lu, H.
McHugh, D.J.
Irlam, J.
West, C.M.
Betts, G.N.
Ashton, G.
Reynolds, A.R.
Maddineni, S.
Clarke, N.W.
Parker, G.J.
Waterton, J.C.
Robinson, S.P.
O'Connor, J.P.
Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology. Radiology,
Vol.288
(3),
pp. 739-747.
show abstract
Purpose To cross-validate T1-weighted oxygen-enhanced (OE) MRI measurements of tumor hypoxia with intrinsic susceptibility MRI measurements and to demonstrate the feasibility of translation of the technique for patients. Materials and Methods Preclinical studies in nine 786-0-R renal cell carcinoma (RCC) xenografts and prospective clinical studies in eight patients with RCC were performed. Longitudinal relaxation rate changes (∆R1) after 100% oxygen inhalation were quantified, reflecting the paramagnetic effect on tissue protons because of the presence of molecular oxygen. Native transverse relaxation rate (R2*) and oxygen-induced R2* change (∆R2*) were measured, reflecting presence of deoxygenated hemoglobin molecules. Median and voxel-wise values of ∆R1 were compared with values of R2* and ∆R2*. Tumor regions with dynamic contrast agent-enhanced MRI perfusion, refractory to signal change at OE MRI (referred to as perfused Oxy-R), were distinguished from perfused oxygen-enhancing (perfused Oxy-E) and nonperfused regions. R2* and ∆R2* values in each tumor subregion were compared by using one-way analysis of variance. Results Tumor-wise and voxel-wise ∆R1 and ∆R2* comparisons did not show correlative relationships. In xenografts, parcellation analysis revealed that perfused Oxy-R regions had faster native R2* (102.4 sec-1 vs 81.7 sec-1) and greater negative ∆R2* (-22.9 sec-1 vs -5.4 sec-1), compared with perfused Oxy-E and nonperfused subregions (all P < .001), respectively. Similar findings were present in human tumors (P < .001). Further, perfused Oxy-R helped identify tumor hypoxia, measured at pathologic analysis, in both xenografts (P = .002) and human tumors (P = .003). Conclusion Intrinsic susceptibility biomarkers provide cross validation of the OE MRI biomarker perfused Oxy-R. Consistent relationship to pathologic analyses was found in xenografts and human tumors, demonstrating biomarker translation. Published under a CC BY 4.0 license. Online supplemental material is available for this article..
Baker, L.C.
Sikka, A.
Price, J.M.
Boult, J.K.
Lepicard, E.Y.
Box, G.
Jamin, Y.
Spinks, T.J.
Kramer-Marek, G.
Leach, M.O.
Eccles, S.A.
Box, C.
Robinson, S.P.
Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma. Frontiers in oncology,
Vol.8.
Jamin, Y.
MRI imaging of the hemodynamic vasculature of neuroblastoma predicts response to anti-angiogenic treatment. Cancer research,
.
Li, J.
Zormpas-Petridis, K.
Boult, J.
Reeves, E.
Chesler, L.
Jones, C.
Bamber, J.
Yuan, Y.
Jamin, Y.
Robinson, S.
Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Non-invasive Magnetic Resonance Elastography. Cancer research,
.
Shah, A.
Delgado-Goni, T.
Casals Galobart, T.
Wantuch, S.
Jamin, Y.
Leach, M.
Robinson, S.
Bamber, J.
Beloueche-Babari, M.
Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging. Scientific reports,
.